Merck KGaA

News

Imec showcases ingestible sensor for gut studies

Imec will demonstrate an ingestible sensor device today that can monitor gut health and could be a valuable tool for research and clinical trials.

News

Belén Garijo, Merck's chair and chief executive

Merck agrees $3.9 billion takeover of SpringWorks

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.

News

Merck puts a price on its SpringWorks takeover bid

Merck KGaA has confirmed that talks to buy SpringWorks have advanced to the 'late-stage' and are revolving around an offer of around $47 per share.

News

Merck MS tablet set for wider use by NHS in England

Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad.

News

Merck confirms its interest in buying SpringWorks

Merck KGaA has acknowledged that it is in talks to buy US cancer SpringWorks, but cautioned there is no guarantee a deal will be forthcoming.

News

Merck drug for rare tumour hits phase 3 target

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 tr

Imec showcases ingestible sensor for gut studies

Merck agrees $3.9 billion takeover of SpringWorks

Merck puts a price on its SpringWorks takeover bid

Merck MS tablet set for wider use by NHS in England

Merck confirms its interest in buying SpringWorks

Merck drug for rare tumour hits phase 3 target

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

Merck KGaA

Editor's Picks